We review the outcomes of ultrasound-guided biopsy in consecutive patients and assess clinical significance of Japanese prostate cancer. Methods: Examination was made of 1469patients subsequent to transrectal ultrasound-guided biopsyof theprostategland. For 84 patients, two or moresetsof ultrasound-guided biopsies were conducted following the initial negative results during this period. Two hundred and thirty-two patients withbenignhistology at the initial biopsy underwent transurethral resection of the prostate (TURP). The clinical significance of the cancers was assessed based on patient age and calculated tumorvolumeat diagnosis, assumed cancervolume doubling timeand life-expectancy in the Japanese male population. Results: Overall, 327 of the 1469patients (22.3%) hadprostate carcinoma. Positive biopsyrates in patients with PSA 2.0 ng/ml or lower, 2.1-4.0 ng/ml, 4.1-10.0 ng/ml and 10.1 ng/ml or greater were 4.6%, 8.6%, 15.80/0 and 59.5%, respectively. Of the 232 patientswho underwent TURP, 15 (6.5%) had cancer. Of the 84 patients subjected to the multiple sets of biopsies, 19 (22.6%) cancers were detected. Of the 203 cancers without distant metastasis at initial biopsy, 13.3%, 25.1 %, 32.5% and 40.4% of tumors for 2-, 3-, 4-and 6-year tumor doubling times gave no indication of clinical significance. Nearly half these patients (43-52%) had clinical stage T1 c disease. The estimated proportion of clinically insignificant tumors in repeat biopsywas virtually the same as first set biopsies. Conclusions: Low PSA was not necessarily an indication of indolentcancer and repeat biopsy did not often demonstrate clinically unimportant cancers. Many patients with stage T1 c disease may eventually prove to require no treatment.
INTRODUCTION
The incidence of prostate cancer is on the rise and presently ranks as the 9th highest cause of male cancer death in Japan 0-3). There were 6482 cases in 1988 and the number is anticipated to increase to as many as 12 783 by 2000. The greater values of statistical data are due in part to the more sensitive detection possible through the use of the prostate-specific antigen (PSA) (4) . Ultrasound-guided biopsy, particularly random sextant 
MATERIALS AND METHODS
Examination was carried out on 1469 consecutive patients subsequent to transrectal ultrasound guided biopsy of the prostate gland at Kitasato University Hospital between October 1991 and October 1997. No patients had previously been diagnosed with prostate cancer or had undergone endocrine manipulation. All patients whose digital rectal examination results appeared questionable and/or with serum PSA greater than 2.0 ng/ml by Eileen polyclonal radioimmunoassay (Eiken, Tokyo, up to March 1993) or 2.0 ng/ml by Dainapack IMx PSA assay (Dinabot, Tokyo, thereafter) underwent biopsy (11) . Of these, 123 underwent biopsy in the PSA-based early detection program at this institution (12) . A lower PSA cut-off value of 2.0 ng/ml in Eiken polyclonal radioimmunoassay and Dainapack IMx PSA assay has been used at this hospital as indication for biopsy instead of recommended values (0-3.0 and 0-4.0 ng/ml, respectively) by the manufacturers (11, 13) . For uniformity, Eiken PSA in 554 patients was inter-converted as recommended by Machida et al.: IMx PSA=I.39xEiken
PSA -1.02 (11) . This conversion arbitrarily gave negative values in IMx PSA in the event of low Eiken PSA. These were taken as o for the purpose of statistical analysis and other calculations.
Biopsy was indicated based in part on pre-prostatectomy evaluation in some patients regardless of clinical fmdings. Most patients (n=1390) underwent ultrasound-guided systematic needle biopsy at six or more separate sites in such a way as to maximize sampling of the peripheral zone (14) . Biopsy specimens from superior, middle and inferior regions were followed by additional needle biopsy of hypoechoic lesions appearing suspicious on ultrasound. A subgroup of 420 patients underwent transition zone sampling at the time of peripheral zone sampling (5) . Seventy-nine patients underwent only biopsy directed at hypoechoic lesions and/or random non-systematic biopsy. Eighty-four patients underwent two or more sets of ultrasound-guided biopsy owing to initial negative results during this period. Indications for repeat biopsy included atypia or prostatic intraepithelial neoplasia on initial biopsy or strong clinical suggestion of carcinoma based on PSA or digital rectal examination. A total of 232 patients underwent TURP following the clinical diagnosis of benign prostatic hyperplasia (BPH) based on negative biopsy results.
Patients with prostate cancer were examined for staging by digital rectal examination, prostatic acid phosphatase, intravenous urography, computed tomography, magnetic resonance imaging and bone scanning, supplemented with radiographs of abnormal areas. Clinical stage was determined in accordance with the unified tumor node metastasis (TNM) system (15) . In this study, data were stratified according to T-and M-stage since nodal status could not be accurately determined using methods currently available. All histology slides were examined and reviewed by a single pathologist (S.K.) and tumor grade was assigned based on the Gleason grading system. Digital rectal examination was conducted by several board-certified urologists who recorded abnormal findings. Prostate scanning and ultrasound-guided biopsy were conducted using the Bruel & Kjaer (Gentofte, Denmark) model 1846 scanner equipped with a 7 MHz multiplanar transducer. PSA density (PSAD) was derived by dividing serum PSA by prostatic volume, as in transrectal ultrasonography. Prostatic volume was determined as prostatic Iengthxwidthxheightxtn/6).
Prostate cancer volume was determinedas described by D' Amico et al. (10, 16) . The clinical significance of cancer was assessed by this calculated volume and criteria of Dugan et al. (6, 8) .
The Mann-Whitney U or Kruskal-Wallistest was conducted for comparison of age, positive biopsy rate, PSA, PSAD and prostatic volume with P values <0.05 as significant. Logistic regression analysis was conducted to assess variables for usefulness to predict cancer in repeat biopsy with other variables controlled.
RESULTS

RESULTS OF INITIAL BIOPSY
The median subject age of the 1469 patients was 67.0 years (range 30-94, Table 2 ). Distant metastasis was found in 30.9% (101/327). Tumor grade distribution was as follows: Gleason score 2-4 in 14.9%,5 and 6 in 29.7%, 7 in 36.7% and 8-10 in 18.7%. Positive biopsy rates in patients with PSA 2.0 ng/ml or lower, 2.1-4.0 ng/ml, 4.1-10.0 ng/ml and 10.1 ng/ml or greater were 4.6%,8.6%, 15.8% and 59.5%, respectively. The incidence of extraglandular disease (2T3) and poorly differentiated histology of Gleason scores 7 or greater in these PSA ranges were 25.0%, 15.6%, 11.0%,51.4% and 58.3%,34.4%,42.5%,62.9%, respectively.
Calculated tumor volume ranged from 0.0 to 14 356.0 cm-' (median 3.9). Graded increase in median values of calculated tumor volume according to PSA was noted: 0.10 cm' for 2.0 ng/ml or lower, 0.19 cm-'for 2.1-4.0 ng/ml, 1.22 cm-' for4.1-10.0 ng/ml and 12.19 cm-' for 10.1 ng/ml or more (P<O.OOOl, Table 2 ).
Rectal findings were significant for predicting prostate cancer and positive results were in proportion to PSA: 8.7% for 2.0 ng/ml or lower, 22.5% for 2.1-4.0 ng/ml, 42.0% for 4.1-10.0 ng/ml and 87.8% for 10.1 ng/ml or more (P<O.OOOI, Table 3 ). Graded increase in detection was also noted for patients with normal rectal findings (P=0.028), as also for patients with negative and positive ultrasound findings or PSAD20.15 (P<O.OOOl). Cancer was found 1.3 times more often for glandular volume of 40.0 cm' or less (P=0.008). 
DISCUSSION
The clinical stages of 82 patients with insignificant tumors for an assumed 6-year doubling time were TIc in 36 (43.9%), T2a in 11
The PSA test is now widely conducted in Japan for making early (13.4%), T2b in 24 (29.3%), T2cin6(7.3%), T3bin 1 (1.2%) and diagnosis of prostate cancer and this malignancy has thus been T3c in 4 (4.9%). Clinically insignificant cancers were present in detected more frequently (1) (2) (3) (4) 12, 17) . The incidence of prostate 9 of27 (33.3%) patients less than 60 years old, in 28 of81 (34.6%) cancer and advanced disease has been shown proportional to patients aged 60-69 years and in 30 of 72 (41.7%) patients aged PSA, as also noted in this study (16) (17) (18) (19) (20) (21) . The cut-off for this test 70-79 patients, 15 of 23 (65.2%) patients over 80 years. Serum is determined by a balance between detecting all cancers as early PSA was inversely correlated with insignificant cancers, 22of 37 as possible and avoidance of biopsy for cases of slight cancer (59.5%) patients for 4.0 ng/ml or lower, 31 of 60 (51.7%) patients possibility. It is known that age specific reference ranges of PSA for 4.1-10.0 ng/ml and 29 of 106 (27.4%) for 10.1 ng/ml or more differ significantly accordingto race (17, 22) . Selection of an ideal western countries. Of 84 patients who underwent multiple sets of biopsy due to initial negative results, 19 (22.6%) cancers were detected. Error in sampling using current biopsy methods rather than racial difference may significantly influence the detection rate in patient groups undergoing repeat biopsy. A single set of biopsies may not make sampling of the prostate sufficiently possible. Better biopsy methods should be established. Fifteen more cancers (6.5%) were diagnosed by TURP. All but one of these 34 patients had clinically localized cancer. One fourth had poorly differentiated tumors of Gleason score 7 or greater. Though Fleshner et al. (25) found PSA at more than 20 ng/ml to be a significant independent risk factor, by multivariate analysis in this study, it was not possible to identify variables useful for predicting the need for repeat biopsies. The assignment of any cancer to an unimportant category must be based on age, health and life expectancy and features of the cancer itself (6, 8) . Based on a modified model of Dugan et al. (8) , clinical significance of Japanese prostate cancer subsequent to radical prostatectomy was assessed previously (6) . However, the results may not necessarily be representative for all prostate cancer patients. The clinical applicability of this model is significantly limited owing to the inability to accurately predict tumor volume prior to treatment. The tumor volume assessment model proposed by D'Amico and Propert (10) was used to investigate clinical significance of Japanese prostate cancer. Of 203 cancers detected by initial biopsy and without distant metastasis (MO), 13.3%, 25.1%, 32.5% and 40.4% of tumors would have been clinically insignificant for assumed 2-,3-,4-and 6-year tumor doubling times, respectively. These percentages exceed those estimated for patients subsequent to radical prostatectomy (6) . Nearly half of these patients (43-52%) had clinical stage TIc disease. There is theoretical concern that repeat biopsy may identify clinically insignificant cancers more often owing to length time bias involved. Tumor grade tends to be more differentiated in cancers detected by repeat biopsy, but the estimated proportion of clinically insignificant tumors was virtually the same as first set biopsies.
The present study has limited scope of application owing to the use of converted PSA data. Estimated tumor volume (calculated tumor volume) and biopsy Gleason score may also give rise to problems. Only modest correlation was found between calculated and measured tumor volumes in patients following radical prostatectomy (1"=0.590). Similar findings were recently noted by Chan et al. (26) . The overall correlation between calculated and measured tumor volumes was much less than that found by D'Amico et al. (0.537 versus 0.98) (10, 16) . Calculated tumor volume may have been less than actual volume. This parameter for 10 tumors was estimated as 0 cm' in our study. Thus, with consideration to trend of undergrading by biopsy cores (18, 19) , some tumors may eventually prove clinically significant. The definition of clinical significance of prostate cancer based only on assumptions on fixed tumor doubling time, life expectancy and other estimates may also be problematic. Current findings and the definition for the clinical significance of prostate cancer should thus be evaluated further for confirmation of validity. In particular, comparative analysis with long-term follow-up data is serum PSA cut-off value for early detection of prostate cancer is thus difficult and should be determined for each race. An arbitrarily chosen lower PSA cut-off value of 2.0 ng/ml in Eiken polyclonal radioimmunoassay and Dainapack IMx PSA assay is generally used at this hospital as an indication for biopsy (5, 16) . Of the 1469 consecutive patients, 631 (43.0%) had a PSA of 4.0 ng/ml or lower. Cancer was detected in 7% (44/631) of men in this low range (11, 13), 4.6% in patients with aPSA of2.0ng/ml or lower and 8.6% in patients with a PSA between 2.1 and 4.0 ng/ml. Approximately half these patients had stage TIc disease. This low rate of detection may not necessarily justify routine use of the lower cut-off value of PSA, but 40.9% (18/44) of tumors had poorly differentiated histology of Gleason scores 7 or greater. Moreover, 18.2% and 13.6% had locally advanced disease and distant metastasis, respectively. Catalona et al. (23) recently reported that prostate cancer could be appreciably detected in men with a PSA of2.6-4.0 ng/ml. Prostate cancer was detected in 22% of 332 screening volunteers aged 50 years or older who had a benign prostate examination. All cancers were clinically localized and for 8.2%, biopsy Gleason score was 7 or greater. Low PSA itself thus would not necessarily indicate indolent cancer. Though direct comparison of both studies may not be possible, disparity in the incidence of aggressive cancer may reflect differences in clinical significance of a given serum PSA in Japanese and Caucasian males of the same age (16, 17) . Lowering the recommended PSA for biopsy may be beneficial for certain Japanese patients.
Approximately 20-30% of men with a PSA higher than 4.0 ng/ml whose initial biopsy showed no prostate cancer are diagnosed as cancer based on subsequent biopsy conducted within a year on average (24, 25) . This study is the first to report results of repeat ultrasound guided biopsy in the Asian male population. The outcomes were similar to previous studies of essential before drawing any meaningful conclusions. Nevertheless, this estimation helped to provide an overview of clinically insignificant cancers detected by ultrasound guided biopsy. More precise estimation will be essential for future study.
CONCLUSION
Earlier detection of prostate cancer in Japan is possible through PSA testing. Low PSA does not necessarily indicate indolent cancer. Reduction in PSA as the indication for biopsy may be beneficial for certain Japanese patients. Many patients with stage TIc disease may eventually prove to require no treatment.
